Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes – AstraZeneca

Written by | 3 May 2021

AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage… read more.

Fish oil supplementation increases atrial fibrillation risk in some patients

Written by | 3 May 2021

Article written by Bruce Sylvester Patients at high risk for cardiovascular disease (CVD) – or who already have established cardiovascular disease and elevated plasma triglycerides — who use… read more.

CHMP recommends approval of Enspryng for neuromyelitis optica spectrum disorder – Roche

Written by | 2 May 2021

Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Enspryng (satralizumab) as the first subcutaneous treatment option… read more.

Frequent internet use by older people during lockdown linked to mental health benefits

Written by | 2 May 2021

A new study from the University of Surrey has found that among people aged 55 to 75 more frequent use of the internet was beneficial for mental health… read more.

Protected: FDA grants accelerated approval for Jemperli in endometrial cancer – GSK

Written by | 1 May 2021

There is no excerpt because this is a protected post.

Pregnant women with COVID-19 face high mortality rate

Written by | 1 May 2021

In a worldwide study of 2,100 pregnant women, those who contracted COVID-19 during pregnancy were 20 times more likely to die than those who did not contract the… read more.

EU CHMP recommends approval of Onureg for acute myeloid leukemia – Bristol Myers Squibb

Written by | 30 Apr 2021

Bristol Myers Squibb has announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Onureg (azacitidine tablets; CC-486) as a… read more.

E-cigarettes plus tobacco cigarettes linked to higher risk of respiratory symptoms

Written by | 30 Apr 2021

Exclusively using (or “vaping”) e-cigarettes can help people quit smoking, but many people using e-cigarettes to quit smoking continue to smoke cigarettes.

Otezla significantly improved measures of disease severity in adults with mild-to-moderate plaque psoriasis – Amgen

Written by | 29 Apr 2021

Amgen announced Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease , according… read more.

Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal

Written by | 29 Apr 2021

Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy… read more.

Johnson & Johnson single-shot COVID-19 vaccine phase III data published in New England Journal of Medicine

Written by | 28 Apr 2021

Johnson & Johnson announced publication in the New England Journal of Medicine of primary data from the Phase III ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed… read more.

Flushing a public toilet? Don’t linger, because aerosolized droplets do!

Written by | 28 Apr 2021

Flushing a toilet can generate large quantities of microbe-containing aerosols depending on the design, water pressure or flushing power of the toilet.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.